Consultation: NENC Methylphenidate for patients within Paediatric Oncology Shared Care Protocol

Following the September 2026 NENC Clinical Guidelines & Pathways Group we now seek comments from across the NENC ICB on this new draft NENC Methylphenidate for patients within Paediatric Oncology Shared Care Protocol.  

This guideline has been developed based on the previous shared care protocol for methylphenidate for this indication from the former North of Tyne, Gateshead & North Cumbria APC which as expired. Methylphenidate was previously approved for this unlicensed indication on the formulary by the North of Tyne, Gateshead & North Cumbria APC in September 2021. All monitoring will be undertaken by the specialist team even after the transfer of prescribing to primary care.

Comments are welcomed from across the system, including residents and patients of the NENC. Comments will be returned to the Clinical Guidelines & Pathways Group/NTAG, and used to inform the final version that is presented for approval in the NENC.

All comments will be reviewed but please do not expect a personal reply as we do not routinely reply to all comments. It is important to include any relevant evidence to back up any suggestions and please keep comments concise where possible.

All comments received will shared unedited with the authors/working group who are developing the document to support the production of a final draft for approval.

Please note

1. The messages sent from this form are transmitted via our host’s web server. If you have any security concerns about this process you can send your comments/feedback using your own email client to nuth.nyrdtc.rxsupp@nhs.net
2. This consultation will run for four weeks and closes on Wednesday 14 October at 5pm.

Name *

Email *

Email

Confirm Email

Job title *

Employer *

Locality

Are you responding on behalf of an organisation or as an individual? *

• On behalf of an organisation or organisational leader
• As an individual

Please specify who you are responding for, including job title and organisation as appropriate

Do you / your organisation support the implementation of this guideline

• Yes
• No

What barriers may prevent you / your organisation from implementing the full guidance?

If there are barriers to implementation what would help resolve these?

Do you have any additional comments?

Submit